Prometheus Biosciences (RXDX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	113.35 mm	113.35 mm	113.35 mm	113.35 mm	113.35 mm	113.35 mm
Cash burn (monthly)	59.69 mm	9.47 mm	16.23 mm	13.53 mm	13.18 mm	11.12 mm
Cash used (since last report)	1.24 bn	196.80 mm	337.24 mm	281.10 mm	273.81 mm	230.94 mm
Cash remaining	-1.13 bn	-83.46 mm	-223.89 mm	-167.75 mm	-160.47 mm	-117.60 mm
Runway (months of cash)	-18.9	-8.8	-13.8	-12.4	-12.2	-10.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

RXDX institutional ownership history Ownership history

16.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	4	219	-98.2%
Opened positions	1	39	-97.4%
Closed positions	216	45	+380.0%
Increased positions	0	89	EXIT
Reduced positions	0	71	EXIT

13F shares	Current	Prev Q	Change
Total value	147.52 mm	4.29 tn	-100.0%
Total shares	7.73 mm	47.68 mm	-83.8%
Total puts	279.60 k	262.60 k	+6.5%
Total calls	74.50 k	676.70 k	-89.0%
Total put/call ratio	3.8	0.4	+867.1%

Largest owners	Shares	Value	Change
Cedars Sinai Intellectual Property	4.00 mm	$0.00	0.0%
Nestle Health Science US	3.73 mm	$147.52 mm	0.0%
Simplex Trading	0.00	$0.00	EXIT
Maven Securities	0.00	$0.00

Largest transactions	Bought/sold	Change
RTW Investments	-3.27 mm	EXIT
BLK BlackRock	-2.80 mm	EXIT
Vanguard	-2.72 mm	EXIT
Boxer Capital	-1.90 mm	EXIT
72 Investment	-1.85 mm	EXIT
Cormorant Asset Management	-1.66 mm	EXIT
Point72 Asset Management	-1.47 mm	EXIT
Fred Alger Management	-1.33 mm	EXIT
Perceptive Advisors	-1.27 mm	EXIT
STT State Street	-1.24 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Press releases

From Benzinga Pro

Cellino Appoints Chris Gibson to Board of Directors

24 Oct 24

Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of